{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:43:57Z","timestamp":1786725837969,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>The relationship between hepatitis C virus (HCV) infection and cardiovascular disease (CVD) is increasingly recognized, with studies indicating elevated CVD prevalence and mortality among individuals with HCV. Chronic HCV patients exhibit a higher CVD risk, especially in the population of end-stage renal disease on hemodialysis. Pathogenic mechanisms may include oxidative stress, endothelial damage, metabolic dysregulation, and chronic inflammation. These factors enhance vascular damage, promoting plaque formation and instability. Direct-acting antivirals (DAAs), which have revolutionized HCV treatment by achieving sustained virologic response rates of over 95%, significantly mitigate CVD risk. DAA therapy improves endothelial function, reduces inflammatory biomarkers, and lowers the incidence of CVD events. However, lipid profiles may paradoxically increase following HCV clearance. In addition, the contrasting outcomes between DAA treatment and arrhythmia risk remain elusive. Potential epigenetic changes for CVD risk may persist after successful viral eradication. The elucidation of unmet needs is critical for solidifying screening guidelines for HCV patients with CVD and for exploration of the long-term CVD outcome in the DAA era.<\/jats:p>","DOI":"10.4103\/tcmj.tcmj_101_25","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T21:02:02Z","timestamp":1754341322000},"page":"371-377","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Hepatitis C virus and cardiovascular disease: Current knowledge and unmet needs"],"prefix":"10.4103","volume":"37","author":[{"given":"Chih-Wen","family":"Wang","sequence":"first","affiliation":[{"name":"Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[{"name":"Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Center for Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[{"name":"Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Center for Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[{"name":"Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Center for Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"R1-20251009","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S2468-1253(19)30227-4","article-title":"Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection:A systematic review, meta-analysis, and modelling study","volume":"4","author":"Lee","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20251009","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/clc.23299","article-title":"Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection:A review","volume":"43","author":"Babiker","year":"2020","journal-title":"Clin Cardiol"},{"key":"R3-20251009","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.3748\/wjg.v24.i41.4617","article-title":"Chronic hepatitis C, atherosclerosis and cardiovascular disease:What impact of direct-acting antiviral treatments?","volume":"24","author":"Adinolfi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R4-20251009","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tem.2009.07.005","article-title":"Hepatitis C virus hijacks host lipid metabolism","volume":"21","author":"Syed","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"R5-20251009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2023.05.003","article-title":"Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals","volume":"375","author":"Casas-Deza","year":"2023","journal-title":"Atherosclerosis"},{"key":"R6-20251009","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/cid\/cix359","article-title":"Risk of acute myocardial infarction among hepatitis C virus (HCV)-positive and HCV-negative men at various lipid levels:Results from ERCHIVES","volume":"65","author":"Butt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R7-20251009","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1607-551X(09)70520-0","article-title":"Hepatitis C virus infection and metabolic syndrome \u2013A community-based study in an endemic area of Taiwan","volume":"25","author":"Huang","year":"2009","journal-title":"Kaohsiung J Med Sci"},{"key":"R8-20251009","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1111\/j.1572-0241.2008.01996.x","article-title":"Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection","volume":"103","author":"Huang","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R9-20251009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.kjms.2012.11.001","article-title":"Glucose abnormalities in hepatitis C virus infection","volume":"29","author":"Huang","year":"2013","journal-title":"Kaohsiung J Med Sci"},{"key":"R10-20251009","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jfma.2023.01.011","article-title":"TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes","volume":"122","author":"Yu","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"R11-20251009","doi-asserted-by":"crossref","first-page":"e035867","DOI":"10.1136\/bmjopen-2019-035867","article-title":"Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection","volume":"10","author":"Badawi","year":"2020","journal-title":"BMJ Open"},{"key":"R12-20251009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.amjms.2024.02.004","article-title":"Hepatitis C virus infection associated with coronary and thoracic aortic atherosclerosis","volume":"368","author":"Wang","year":"2024","journal-title":"Am J Med Sci"},{"key":"R13-20251009","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/JCMA.0000000000000312","article-title":"Risk of hepatitis C virus infection in injecting and noninjecting drug users receiving opioid substitution therapy","volume":"83","author":"Wang","year":"2020","journal-title":"J Chin Med Assoc"},{"key":"R14-20251009","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1093\/cid\/ciaa1014","article-title":"Atherosclerotic cardiovascular events in patients infected with human immunodeficiency virus and hepatitis C virus","volume":"72","author":"Tan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R15-20251009","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases:A community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"key":"R16-20251009","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/MEG.0000000000002558","article-title":"The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease","volume":"35","author":"Tsai","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R17-20251009","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk:Epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"R18-20251009","doi-asserted-by":"crossref","first-page":"e13432","DOI":"10.1002\/aid2.13432","article-title":"Hepatitis C virus infection increases risk of peripheral arterial disease in end-stage renal disease patients receiving maintenance hemodialysis therapy","author":"Wang","year":"2025","journal-title":"Adv Dig Med"},{"key":"R19-20251009","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/QAD.0b013e32833ce54d","article-title":"Hepatitis C virus infection is associated with endothelial dysfunction in HIV\/hepatitis C virus coinfected patients","volume":"24","author":"de Castro","year":"2010","journal-title":"AIDS"},{"key":"R20-20251009","doi-asserted-by":"crossref","first-page":"e1585","DOI":"10.1097\/MD.0000000000001585","article-title":"Hepatitis C virus infection associated with an increased risk of deep vein thrombosis:A population-based cohort study","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R21-20251009","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.3350\/cmh.2024.0638","article-title":"Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma:Inflictor or bystander?Correspondence to editorial on \u201cdynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication:A nationwide registry study in Taiwan\u201d","volume":"31","author":"Huang","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"R22-20251009","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2022.01.029","article-title":"Metabolic dysfunction and cancer in HCV:Shared pathways and mutual interactions","volume":"77","author":"Leslie","year":"2022","journal-title":"J Hepatol"},{"key":"R23-20251009","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2018.11.022","article-title":"Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events","volume":"156","author":"Butt","year":"2019","journal-title":"Gastroenterology"},{"key":"R24-20251009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J Hepatol"},{"key":"R25-20251009","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/pds.5651","article-title":"Association between treatment of hepatitis C virus and risk of cardiovascular disease among insured patients with the virus in the United States","volume":"32","author":"Wang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R26-20251009","doi-asserted-by":"crossref","first-page":"e194765","DOI":"10.1001\/jamanetworkopen.2019.4765","article-title":"Assessing the safety of direct-acting antiviral agents for hepatitis C","volume":"2","author":"McGlynn","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R27-20251009","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/pds.5576","article-title":"Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers","volume":"32","author":"Lam","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R28-20251009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2020.01.010","article-title":"Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events:A prospective multicentre study","volume":"296","author":"Adinolfi","year":"2020","journal-title":"Atherosclerosis"},{"key":"R29-20251009","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kjms.2017.07.003","article-title":"The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents","volume":"33","author":"Huang","year":"2017","journal-title":"Kaohsiung J Med Sci"},{"key":"R30-20251009","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/kjm2.12275","article-title":"Cure or curd:Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication","volume":"36","author":"Huang","year":"2020","journal-title":"Kaohsiung J Med Sci"},{"key":"R31-20251009","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/jvh.13469","article-title":"Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes:A systematic review and meta-analysis","volume":"28","author":"Su","year":"2021","journal-title":"J Viral Hepat"},{"key":"R32-20251009","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/liv.15876","article-title":"Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities:A systematic review","volume":"44","author":"Cespiati","year":"2024","journal-title":"Liver Int"},{"key":"R33-20251009","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11739-019-02163-8","article-title":"Direct-acting antivirals improve endothelial function in patients with chronic hepatitis:A prospective cohort study","volume":"15","author":"Di","year":"2020","journal-title":"Intern Emerg Med"},{"key":"R34-20251009","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijcard.2018.04.058","article-title":"Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function","volume":"271","author":"Schmidt","year":"2018","journal-title":"Int J Cardiol"},{"key":"R35-20251009","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1002\/ctm2.275","article-title":"Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation","volume":"11","author":"Rey","year":"2021","journal-title":"Clin Transl Med"},{"key":"R36-20251009","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C:Final update of the series(\u2606)","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"R37-20251009","first-page":"479","article-title":"2024 guidelines of the Taiwan Society of Cardiology on the primary prevention of atherosclerotic cardiovascular disease \u2013Part I","volume":"40","author":"Chao","year":"2024","journal-title":"Acta Cardiol Sin"},{"key":"R38-20251009","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"R39-20251009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","article-title":"EASL position paper on clinical follow-up after HCV cure","volume":"81","author":"Reiberger","year":"2024","journal-title":"J Hepatol"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_101_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:26:23Z","timestamp":1786724783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_101_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_101_25","relation":{},"ISSN":["1016-3190","2223-8956"],"issn-type":[{"value":"1016-3190","type":"print"},{"value":"2223-8956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"2025-03-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}